PMID- 18495848
OWN - NLM
STAT- MEDLINE
DCOM- 20081007
LR  - 20211020
IS  - 1556-679X (Electronic)
IS  - 1556-6811 (Print)
IS  - 1556-679X (Linking)
VI  - 15
IP  - 8
DP  - 2008 Aug
TI  - Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on 
      antibody responses to erythrocytic-stage Plasmodium falciparum antigens in 
      infants in Mozambique.
PG  - 1282-91
LID - 10.1128/CVI.00044-08 [doi]
AB  - We evaluated the impact of intermittent preventive treatment in infants (IPTi) 
      with sulfadoxine-pyrimethamine (SP), which was given at ages 3, 4, and 9 months 
      through the Expanded Program on Immunization (EPI), on the development of 
      antibody responses to Plasmodium falciparum in Mozambique. Immunoglobulin M (IgM) 
      and IgG subclass antibodies specific to whole asexual parasites and to 
      recombinant MSP-1(19), AMA-1, and EBA-175 were measured at ages 5, 9, 12, and 24 
      months for 302 children by immunofluorescence antibody tests and by enzyme-linked 
      immunosorbent assays. Antibody responses did not significantly differ between 
      children receiving IPTi with SP and those receiving a placebo at any time point 
      measured, with the exception of the responses of IgG and IgG1 to AMA-1 and/or 
      MSP-1(19), which were significantly higher in the SP-treated group than in the 
      placebo group at ages 5, 9, and/or 24 months. IPTi with SP given through the EPI 
      reduces the frequency of malarial illness while allowing the development of 
      naturally acquired antibody responses to P. falciparum antigens.
FAU - Quelhas, Diana
AU  - Quelhas D
AD  - Centro de Investigacao em Saude da Manhica (CISM), Manhica, Mozambique.
FAU - Puyol, Laura
AU  - Puyol L
FAU - Quinto, Llorenc
AU  - Quinto L
FAU - Serra-Casas, Elisa
AU  - Serra-Casas E
FAU - Nhampossa, Tacilta
AU  - Nhampossa T
FAU - Macete, Eusebio
AU  - Macete E
FAU - Aide, Pedro
AU  - Aide P
FAU - Mayor, Alfredo
AU  - Mayor A
FAU - Mandomando, Inacio
AU  - Mandomando I
FAU - Sanz, Sergi
AU  - Sanz S
FAU - Aponte, John J
AU  - Aponte JJ
FAU - Chauhan, Virander S
AU  - Chauhan VS
FAU - Chitnis, Chetan E
AU  - Chitnis CE
FAU - Alonso, Pedro L
AU  - Alonso PL
FAU - Menendez, Clara
AU  - Menendez C
FAU - Dobano, Carlota
AU  - Dobano C
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080521
PL  - United States
TA  - Clin Vaccine Immunol
JT  - Clinical and vaccine immunology : CVI
JID - 101252125
RN  - 0 (Antibodies, Protozoan)
RN  - 0 (Antigens, Protozoan)
RN  - 0 (Antimalarials)
RN  - 0 (Drug Combinations)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Recombinant Proteins)
RN  - 37338-39-9 (fanasil, pyrimethamine drug combination)
RN  - 88463U4SM5 (Sulfadoxine)
RN  - Z3614QOX8W (Pyrimethamine)
SB  - IM
MH  - Animals
MH  - Antibodies, Protozoan/*blood
MH  - Antigens, Protozoan/genetics/*immunology
MH  - *Antimalarials/administration & dosage/therapeutic use
MH  - Child, Preschool
MH  - Drug Administration Schedule
MH  - Drug Combinations
MH  - Erythrocytes/parasitology
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Immunoglobulin M/blood
MH  - Infant
MH  - Malaria, Falciparum/immunology/*prevention & control
MH  - Mozambique
MH  - Plasmodium falciparum/*immunology
MH  - *Pyrimethamine/administration & dosage/therapeutic use
MH  - Recombinant Proteins/genetics/immunology
MH  - *Sulfadoxine/administration & dosage/therapeutic use
MH  - Treatment Outcome
PMC - PMC2519318
EDAT- 2008/05/23 09:00
MHDA- 2008/10/08 09:00
PMCR- 2009/02/01
CRDT- 2008/05/23 09:00
PHST- 2008/05/23 09:00 [pubmed]
PHST- 2008/10/08 09:00 [medline]
PHST- 2008/05/23 09:00 [entrez]
PHST- 2009/02/01 00:00 [pmc-release]
AID - CVI.00044-08 [pii]
AID - 0044-08 [pii]
AID - 10.1128/CVI.00044-08 [doi]
PST - ppublish
SO  - Clin Vaccine Immunol. 2008 Aug;15(8):1282-91. doi: 10.1128/CVI.00044-08. Epub 
      2008 May 21.